2.Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.
4.Mogensen CE. New treatment guidelines for a patient with diabetes and hypertension. J Hypertens Suppl 2003;21:S25-30.
5.Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elm-feldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62.
6.Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlöf B, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010;375:895-905.
7.Mehlum MH, Liest⊘l K, Kjeldsen SE, Julius S, Hua TA, Rothwell PM, et al. Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks. Eur Heart J 2018;39:2243-51.
9.Wu C, Shlipak MG, Stawski RS, Peralta CA, Psaty BM, Harris TB, et al. Visit-to-visit blood pressure variability and mortality and cardiovascular outcomes among older adults: the Health, Aging, and Body Composition Study. Am J Hypertens 2017;30:151-8.
10.Imai Y, Aihara A, Ohkubo T, Nagai K, Tsuji I, Minami N, et al. Factors that affect blood pressure variability. A com-munity-based study in Ohasama, Japan. Am J Hypertens 1997;10:1281-9.
11.Sethi BK, Baruah MP, Kumar AS. Blood pressure variability in patients with diabetes mellitus with hypertension: treatment recommendations and role of amlodipine. J Assoc Physicians India 2017;65:67-71.
12.Spallone V. Blood pressure variability and autonomic dysfunction. Curr Diab Rep 2018;18:137.
13.Weston KS, Sacre JW, Jellis CL, Coombes JS. Contribution of autonomic dysfunction to abnormal exercise blood pressure in type 2 diabetes mellitus. J Sci Med Sport 2013;16:8-12.
14.Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010;55:1318-27.
15.Prenner SB, Chirinos JA. Arterial stiffness in diabetes mellitus. Atherosclerosis 2015;238:370-9.
16.Ben-Shlomo Y, Spears M, Boustred C, May M, Anderson SG, Benjamin EJ, et al. Aortic pulse wave velocity im-proves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol 2014;63:636-46.
17.Hata J, Arima H, Rothwell PM, Woodward M, Zoungas S, Anderson C, et al. Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. Circulation 2013;128:1325-34.
18.Zoppini G, Verlato G, Targher G, Bonora E, Trombetta M, Muggeo M. Variability of body weight, pulse pressure and glycaemia strongly predict total mortality in elderly type 2 diabetic patients. The Verona Diabetes Study. Diabetes Metab Res Rev 2008;24:624-8.
19.Yu ZB, Wang JB, Li D, Chen XY, Lin HB, Chen K. Prognostic value of visit-to-visit systolic blood pressure variability related to diabetic kidney disease among patients with type 2 diabetes. J Hypertens 2019;37:1411-8.
20.Wan EY, Fung CS, Yu EY, Fong DY, Chen JY, Lam CL. Association of visit-to-visit variability of systolic blood pressure with cardiovascular disease and mortality in primary care Chinese patients with type 2 diabetes-a retrospective population-based cohort study. Diabetes Care 2017;40:270-9.
21.Viazzi F, Bonino B, Mirijello A, Fioretto P, Giorda C, Ce-riello A, et al. Long-term blood pressure variability and development of chronic kidney disease in type 2 diabetes. J Hypertens 2019 37:805-13. Erratum in: J Hypertens 2020;38:980.
22.Takao T, Suka M, Yanagisawa H, Matsuyama Y, Iwamoto Y. Predictive ability of visit-to-visit variability in HbA1c and systolic blood pressure for the development of microalbu-minuria and retinopathy in people with type 2 diabetes. Diabetes Res Clin Pract 2017;128:15-23.
23.Takao T, Matsuyama Y, Yanagisawa H, Kikuchi M, Kawazu S. Visit-to-visit variability in systolic blood pressure predicts development and progression of diabetic nephropathy, but not retinopathy, in patients with type 2 diabetes. J Diabetes Complications 2014;28:185-90.
24.Sohn MW, Epstein N, Huang ES, Huo Z, Emanuele N, Stukenborg G, et al. Visit-to-visit systolic blood pressure variability and microvascular complications among patients with diabetes. J Diabetes Complications 2017;31:195-201.
26.McMullan CJ, Lambers Heerspink HJ, Parving HH, Dw-yer JP, Forman JP, de Zeeuw D. Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial. Am J Kidney Dis 2014;64:714-22.
28.Hsieh YT, Tu ST, Cho TJ, Chang SJ, Chen JF, Hsieh MC. Visit-to-visit variability in blood pressure strongly predicts all-cause mortality in patients with type 2 diabetes: a 5·5-year prospective analysis. Eur J Clin Invest 2012;42:245-53.
29.Ohkuma T, Woodward M, Jun M, Muntner P, Hata J, Co-lagiuri S, et al. Prognostic value of variability in systolic blood pressure related to vascular events and premature death in type 2 diabetes mellitus: the ADVANCE-ON study. Hypertension 2017;70:461-8.
31.Chiriacò M, Pateras K, Virdis A, Charakida M, Kyriako-poulou D, Nannipieri M, et al. Association between blood pressure variability, cardiovascular disease and mortality in type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 2019;21:2587-98.
32.Noshad S, Mousavizadeh M, Mozafari M, Nakhjavani M, Esteghamati A. Visit-to-visit blood pressure variability is related to albuminuria variability and progression in patients with type 2 diabetes. J Hum Hypertens 2014;28:37-43.
33.Rizzoni D, Muiesan ML, Porteri E, Salvetti M, Castellano M, Bettoni G, et al. Relations between cardiac and vascular structure in patients with primary and secondary hypertension. J Am Coll Cardiol 1998;32:985-92.
34.Rizzoni D, Agabiti-Rosei C, Agabiti-Rosei E. Hemody-namic consequences of changes in microvascular structure. Am J Hypertens 2017;30:939-46.
35.Flynn MD, Tooke JE. Diabetic neuropathy and the micro-circulation. Diabet Med 1995;12:298-301.
37.Zhou TL, Henry RMA, Stehouwer CDA, van Sloten TT, Reesink KD, Kroon AA. Blood pressure variability, arterial stiffness, and arterial remodeling. Hypertension 2018;72:1002-10.
38.Nichols WW, Nicolini FA, Pepine CJ. Determinants of isolated systolic hypertension in the elderly. J Hypertens Suppl 1992;10:S73-7.
39.Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996;275:1571-6.
40.Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012 380:2224-60. Erratum in: Lancet 2013, 381, 1276 Erratum in: Lancet 2013;381:628.
41.Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001;345:1291-7.
43.Parati G, Ochoa JE, Lombardi C, Bilo G. Blood pressure variability: assessment, predictive value, and potential as a therapeutic target. Curr Hypertens Rep 2015;17:537.
44.Veloudi P, Sharman JE. Methodological factors affecting quantification of blood pressure variability: a scoping review. J Hypertens 2018;36:711-9.
45.Wang J, Shi X, Ma C, Zheng H, Xiao J, Bian H, et al. Vis-it-to-visit blood pressure variability is a risk factor for all-cause mortality and cardiovascular disease: a systematic review and meta-analysis. J Hypertens 2017;35:10-7.